Introduction Because of the high mortality of invasive fungal infections (IFIs), appropriate
exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials …

Initial adequate anti-infective therapy is associated with significantly improved clinical
outcomes for patients with severe infections. However, in critically ill patients, several …

Voriconazole is approved for treating invasive fungal infections. We examined voriconazole
exposure-response relationships for patients from nine published clinical trials. The …

Background Voriconazole pharmacokinetic and pharmacodynamic data are lacking in
children. Methods Records at the Childrens Hospital Los Angeles were reviewed for …

Therapeutic drug monitoring (TDM) may be required to achieve optimal clinical outcomes in
the setting of significant pharmacokinetic variability, a situation that applies to a number of …

Objectives The objectives of this study were to explore inter-study heterogeneity in the
pharmacokinetics (PK) of orally administered rifampicin, to derive summary estimates of …

The number of agents available to treat fungal infections has increased by 30% since the
year 2000, yet still only 15 agents are currently approved for clinical use. The greater …

Posaconazole has become an important part of the antifungal armamentarium in the
prophylaxis and salvage treatment of invasive fungal infections (IFIs). Structurally related to …

Abstract Background and Objective: Posaconazole (Noxafil®) is an extended-spectrum
triazole antifungal agent for prevention and treatment of invasive fungal infections. An …

Therapeutic drug monitoring (TDM) may contribute to optimizing the efficacy and safety of
antifungal therapy because of the large variability in drug pharmacokinetics. Rapid …